ROCKLAND IMMUNOCHEMICALS, INC.

Biotech · Private

Bispecific nanobodies for pretargeted radioimmunotherapy and cancer imaging

Grants
$564K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Antibody-based Point-of-Care Device for the Diagnosis of Sickle Cell Disease$224,635
Federal grantDepartment of Health and Human Services · Phase I · Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings$40,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3225CLARADELE PHARMACEUTICALS, INCORPORATED——
3226Quercus Molecular Design, LLC——
3227CELLGORTHMICS, INC——
3228ROCKLAND IMMUNOCHEMICALS, INC.——
3229GATACA, LLC——
3230KADVAX TECHNOLOGIES, INC.——
3231SONOVAL LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Proteins And Method For Detection Of Lyme Diseaseapplication
  • Monoclonal Antibody Panels For Detection Of Chemically Modified Oligonucleotidesapplication
  • Monoclonal Antibody Panels For Detection Of Chemically Modified Oligonucleotidesapplication
  • Monoclonal Antibody Panels For Detection Of Chemically Modified Oligonucleotidesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.